Amgen (AMGN) Tops Q2 EPS by 16c, Lifts FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen Reports Second Quarter 2017 Financial Results
July 25, 2017 4:01 PM EDTTHOUSAND OAKS, Calif., July 25, 2017 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2017. Key results include:
Total revenues increased 2 percent versus the second quarter of 2016 to $5.8 billion. Product sales grew 2 percent driven by Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). GAAP earnings per share (EPS) increased 18 percent to $2.91 driven by higher operating margins. GAAP operating income increased 13 percent to $2.7 billion and GAAP operating margin increased 4.9 percentage points to 48.4 percent. Non-GAAP EPS increased 15 percent to $3.27 driven by higher... More